Safety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-04-30

Study Completion Date

2019-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety of inhaled carbon monoxide (iCO) in intubated patients with sepsis-induced ARDS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)

NCT04870125

Acute Respiratory Distress Syndrome Sepsis

ACTIVE_NOT_RECRUITING PHASE1

Safety and Efficacy Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)

NCT03799874

Acute Respiratory Distress Syndrome

ACTIVE_NOT_RECRUITING PHASE2

Carbon Monoxide to Prevent Lung Inflammation

NCT00094406

Respiratory Distress Syndrome, Adult

COMPLETED PHASE1

Efficacy and Safety Evaluation of BZ371B in ARDS Patients

NCT05384379

ARDS ARDS, Human Pulmonary Disease

TERMINATED EARLY_PHASE1

High Flow Nasal Canula Oxygen Helps Preoxygenate ARDS Patients

NCT02214576

Acute Respiratory Distress Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The acute respiratory distress syndrome (ARDS) is a syndrome of severe acute lung inflammation and hypoxemic respiratory failure with an incidence of 180,000 cases annually in the U.S.Despite decades of research and recent advances in lung protective ventilator strategies, morbidity and mortality remain unacceptably high. Furthermore, no specific effective pharmacologic therapies currently exist. The lack of specific effective therapies for sepsis-related ARDS indicates a need for new treatments that target novel pathways. Carbon monoxide (CO) represents a novel therapeutic modality in ARDS based on data obtained in experimental models of ARDS and sepsis over the past decade.

CO has been shown to be protective in experimental models of Acute Lung Injury (ALI), including hyperoxia and endotoxin exposure, bleomycin, ischemia/reperfusion, and ventilator-induced lung injury (VILI). At low doses, CO has been shown to confer tissue protective effects in these ALI models. In addition, CO has been shown to decrease inflammation, enhance phagocytosis, and improve mortality in models of sepsis including endotoxemia, hemorrhagic shock, and cecal ligation and puncture (CLP). CO has also been shown to have beneficial therapeutic effects in pre-clinical models of disease including pulmonary hypertension, vascular injury, and transplantation. Furthermore, multiple human studies have demonstrated that experimental administration of several different concentrations of CO is well tolerated and that low dose inhaled CO can be safely administered to subjects in a controlled research environment.

The purpose of this study is to assess the safety of inhaled CO therapy in mechanically ventilated patients with sepsis-induced ARDS.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Respiratory Distress Syndrome (ARDS)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

Inhaled Carbon Monoxide at 100 ppm for up to 90 minutes daily for 5 days

Group Type EXPERIMENTAL

Inhaled Carbon Monoxide at 100ppm (4 participants)

Intervention Type DRUG

Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days

Cohort 1 (placebo)

Inhaled Medical Air for up to 90 minutes daily for 5 days

Group Type PLACEBO_COMPARATOR

Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)

Intervention Type DRUG

Inhaled Medical Air for up to 90 minutes daily for 5 days

Cohort 2

Inhaled Carbon Monoxide at 200 ppm for up to 90 minutes daily for 5 days

Group Type EXPERIMENTAL

Inhaled Carbon Monoxide at 200ppm (4 participants)

Intervention Type DRUG

Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days

Cohort 2 (Placebo)

Inhaled Medical Air for up to 90 minutes daily for 5 days

Group Type PLACEBO_COMPARATOR

Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)

Intervention Type DRUG

Inhaled Medical Air for up to 90 minutes daily for 5 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inhaled Carbon Monoxide at 100ppm (4 participants)

Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days

Intervention Type DRUG

Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)

Inhaled Medical Air for up to 90 minutes daily for 5 days

Intervention Type DRUG

Inhaled Carbon Monoxide at 200ppm (4 participants)

Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days

Intervention Type DRUG

Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)

Inhaled Medical Air for up to 90 minutes daily for 5 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

iCO Inhaled Medical Air iCO Inhaled Medical Air

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with sepsis are defined as those with suspected or documented infection:

Suspected or proven infection: Sites of infection include thorax, urinary tract, abdomen, skin, sinuses, central venous catheters, and central nervous system

All eligible patients meet the new definition of sepsis (suspected or proven infection and a SOFA ≥ 2) as PaO2/FiO2 ratio \< 300 = 2 SOFA points.
2. ARDS is defined when all four of the following criteria are met:

* A PaO2/FiO2 ratio ≤ 300 with at least 5 cm H2O positive end-expiratory airway pressure (PEEP)
* Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph
* A need for positive pressure ventilation by an endotracheal or tracheal tube
* No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.
3. ARDS onset is defined as the time the last of criteria 1-4 are met. ARDS must persist through the enrollment time window of 120 hours.
4. Infiltrates considered "consistent with pulmonary edema" include any infiltrates not fully explained by mass, atelectasis, or effusion or opacities known to be chronic (greater than 1 week). Vascular redistribution, indistinct vessels, and indistinct heart borders alone are not considered "consistent with pulmonary edema" and thus would not count as qualifying opacities for this study.

Exclusion Criteria

1. Age less than 18 years
2. Greater than 120 hours since ARDS onset
3. Pregnant or breast-feeding
4. Prisoner
5. Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest)
6. No consent/inability to obtain consent
7. Physician refusal to allow enrollment in the trial
8. Moribund patient not expected to survive 24 hours
9. No arterial line/no intent to place an arterial line
10. No intent/unwillingness to follow lung protective ventilation strategy
11. Severe hypoxemia defined as oxygenation saturation (SpO2) \<95 or PaO2 \<80 on FiO2 ≥0.8
12. Hemoglobin \< 7.5 g/dl or hemoglobin \< 8 g/dl and actively bleeding
13. Subjects who are Jehovah's Witnesses or are otherwise unable or unwilling to receive blood transfusions during hospitalization
14. Acute myocardial infarction (MI) or acute coronary syndrome (ACS) within the last 90 days
15. Coronary artery bypass graft (CABG) surgery within 30 days
16. Angina pectoris or use of nitrates with activities of daily living
17. Cardiopulmonary disease classified as New York Heart Association (NYHA) class IV
18. Stroke (ischemic or hemorrhagic) within the prior 3 months
19. Diffuse alveolar hemorrhage from vasculitis
20. Use of high frequency ventilation
21. Participation in other interventional studies involving investigational agents
22. Burns \> 40% total body surface area
23. Use of inhaled pulmonary vasodilator therapy (eg. NO or prostaglandins)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No